Today's Peptide News — September 23, 2026

A new bioRxiv preprint from Hovakim Sahakyan, Yuri Wolf, and Eugene Koonin (NIH) presents AMES, an atomistic molecular evolution simulator, to test whether short, non-templated peptides could have accelerated the evolution of RNA in the earliest stages of life. Their simulations show that random short peptides stabilize RNA folds, speed up RNA evolution, and boost the structural diversity of evolving RNA molecules — supporting the idea that life's origin was better described as an "RNA-peptide world" than a pure RNA world.

The finding matters because it addresses a long-standing gap in origin-of-life chemistry: RNA alone struggles to explain the leap to the complex, catalytically active molecules needed for early life, and this work offers a mechanistic, testable account of how peptides could have filled that gap well before the ribosome and genetic code existed.

For PeptideWiki, this is a strong candidate for a short explainer post on the deep evolutionary role of peptides — framed around "the first peptides weren't drugs, they were RNA's earliest partners" — with a plain-language walkthrough of what AMES simulated and why peptide-RNA cooperation is now a leading model for prebiotic chemistry.

A newly reported systematic review and meta-analysis of head-to-head trials comparing the GLP-1/GIP dual agonist tirzepatide against semaglutide found tirzepatide produced significantly greater weight loss (roughly 4.3 additional percentage points of body weight, and about 4.4 kg more in absolute terms) and better glycemic control. However, tirzepatide was also linked to a higher rate of serious adverse events — 5.7% versus 2.9% for semaglutide, a nearly twofold relative risk — though the two drugs did not differ in how often patients discontinued treatment because of side effects.

This matters because tirzepatide and semaglutide are the two dominant peptide-based incretin therapies driving the obesity-drug boom, and this analysis gives prescribers and patients one of the clearer efficacy-versus-safety trade-off pictures yet published, at a moment when both drugs are being used by millions of people long-term.

A good PeptideWiki angle is a straightforward "which one, and why" comparison post: lay out the weight-loss and glycemic numbers side by side with the adverse-event data, and note that the safety gap didn't translate into more people quitting treatment — useful context for readers trying to interpret their own prescribing conversations.

The FDA released revised draft product-specific guidances on July 28, 2026 covering reference drugs for 17 peptide products used in type 2 diabetes, obesity, osteoporosis, and macular degeneration — including semaglutide, tirzepatide, liraglutide, teriparatide, and pegcetacoplan. The public docket comment period closes September 28, 2026, giving generic and biosimilar developers a narrow window to weigh in before the guidance is finalized.

This is a regulatory housekeeping story with outsized downstream effects: product-specific guidances set the bioequivalence and testing bar that generic peptide manufacturers must clear, so revisions here shape how quickly (and cheaply) copies of blockbuster peptide drugs can reach patients once patents expire.

An FDA advisory committee voted to recommend adding six unapproved peptides — BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax — to the agency's 503A bulk compounding list, which would let compounding pharmacies produce them for patient-specific prescriptions covering wound healing, ulcerative colitis, weight loss, migraines, pain, and insomnia. The panel rejected a seventh candidate, emideltide, for opioid withdrawal and sleep disorders. Notably, FDA's own scientific reviewers had recommended against adding any of the peptides, citing insufficient robust clinical evidence and unresolved safety questions.

The split between the advisory panel's vote and FDA staff's more cautious recommendation is the real story here — it captures the current tension in the peptide space between fast-growing off-label and biohacker demand (these are among the most talked-about "research peptides" online) and the FDA's traditional evidence bar for compounded drugs.

Samsung Biologics is raising roughly 3 trillion won (about $2.2 billion) through a rights offering to fund the acquisition of PolyPeptide Group, a global peptide contract development and manufacturing organization (CDMO). The move is a direct bet on continued growth in demand for peptide manufacturing capacity as the obesity-drug market expands.

This is one of the largest peptide-manufacturing deals of the year and signals that major biologics players see peptide CDMO capacity — not just peptide drug development — as the next big bottleneck and growth opportunity in the GLP-1 era.

System, a startup building a vertically integrated peptide platform spanning compounding pharmacy operations, clinician matching, and planned API manufacturing, announced a $20 million funding round on September 9, 2026, backed by Patron Fund, Will Ventures, Vine, Courtside, Daybreak, SV Angel, and RiverPark Ventures. The company's pitch is to own the full peptide supply chain end-to-end rather than operate as a single link in it.

It's a smaller deal than the Samsung-PolyPeptide acquisition but illustrates the same trend from the other direction: venture money is chasing peptide infrastructure, not just individual peptide drugs, as consumer and clinical demand broadens.

Eli Lilly now says it expects to file its FDA application for retatrutide — a triple agonist hitting the GIP, GLP-1, and glucagon receptors — in the first quarter of 2027, later than earlier company guidance that had pointed to a possible submission by the end of 2026. Retatrutide has previously shown strong results in trials, including up to an 82% reduction in liver fat in a Phase 2a study of patients with metabolic dysfunction-associated steatotic liver disease.

The delay matters for the broader obesity-drug pipeline: retatrutide is widely viewed as a potential next-generation successor to tirzepatide, and a later filing pushes back the timeline for a three-hormone therapy that could set a new efficacy bar in the category.

New EEG research shows caffeine can degrade the quality of deep sleep even when someone falls asleep normally and logs a full eight hours in bed. Researchers found reduced slow-wave activity — the brain-wave signature of deep, restorative sleep — meaning total sleep time alone doesn't capture how caffeine quietly undermines the sleep stages responsible for physical recovery and memory consolidation.

A brain-imaging study from the Centre for Addiction and Mental Health, following 24 adults with long COVID and 24 matched healthy controls from 2022–2025, found up to 20% lower density of dopamine-releasing neurons in the striatum of long COVID patients using PET imaging of the VMAT2 marker. The pattern of loss tracked with specific symptoms: reduced markers in the ventral striatum correlated with lower motivation, in the dorsal putamen with slowed movement, and in the caudate with memory difficulties.

The study is the strongest evidence yet of a specific, measurable brain injury underlying long COVID's most disabling cognitive and motivational symptoms, and it opens the door to testing dopamine-targeted treatments that are already approved for other conditions.

Astronomers have confirmed Elias 2-24 b, a Jupiter-mass planet orbiting a star roughly 450 light-years away, as the youngest known planet at less than one million years old. The planet sits about 55 times farther from its star than Earth is from the Sun and is still gathering material from its surrounding disk, giving researchers a live look at giant-planet formation in progress.

The discovery challenges existing planet-formation models, which predicted a Jupiter-sized planet at that orbital distance should take roughly five million years or more to form — meaning Elias 2-24 b grew far faster than current theory allows.

Stanford engineers, led by postdoctoral scholar Shoshana Williams and professor Eric Appel, used an AI system to screen a virtual library of 1.7 million synthetic candidates and identify ten highly potent antimicrobial polymers that replicate how natural antimicrobial peptides physically rupture bacterial membranes rather than attacking them chemically. All ten performed well against E. coli in lab tests, and one was especially effective against biofilms.

The appeal of this approach is that natural antimicrobial peptides are short-lived and expensive to manufacture at scale, while these engineered polymers aim to reproduce the same resistance-evading, membrane-disrupting mechanism in a more stable, cheaper form — a potentially important new lead in the fight against drug-resistant bacteria.